Press release
Top Companies and Market Competition in the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Industry
Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
Projected Market Size and Growth Trajectory of Sphingosine 1 Phosphate Receptor Modulator Drugs
The S1PR modulator drugs market is set to experience substantial growth, reaching $3.37 billion by 2030. This expansion corresponds to a compound annual growth rate of 5.5%. The expected surge in market size is driven by factors such as a rising number of multiple sclerosis patients, the broadening of S1PR drug pipelines, increased preference for oral immunotherapies, higher diagnosis rates of autoimmune diseases, and wider adoption of specialty clinics. Key trends during this period include greater use of immune cell trafficking modulators, enhanced uptake in multiple sclerosis treatment, expansion of oral immunomodulatory therapies, more focused targeted immune modulation, and increased application in chronic autoimmune disorders.
Download a free sample of the sphingosine 1 phosphate receptor (s1pr) modulator drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21288&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Factors Fueling Growth in the Sphingosine 1 Phosphate Receptor Modulator Drugs Market
The expanding population of multiple sclerosis patients is a significant contributor to the growth of the S1PR modulator drugs market. As more people are diagnosed with this condition, the demand for effective treatment options rises, encouraging pharmaceutical innovation and market expansion.
Additionally, the growing preference for oral immunotherapies provides a convenient and patient-friendly alternative to traditional injectable treatments. This shift is promoting higher patient adherence and broadening the market reach for S1PR modulators, especially in the treatment of autoimmune diseases.
Leading Companies Driving the S1PR Modulator Drugs Market Forward
Several prominent pharmaceutical companies hold a strong presence in the S1PR modulator drugs industry. These include Novartis International AG, Bristol Myers Squibb Company, Celgene Corporation, Biogen Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Ventyx Biosciences Inc., Arena Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., KYORIN Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., Vanda Pharmaceuticals Inc., Juvisé Pharmaceuticals, Priothera Limited, and Teva Pharmaceutical Industries Ltd.
View the full sphingosine 1 phosphate receptor (s1pr) modulator drugs market report:
https://www.thebusinessresearchcompany.com/report/sphingosine-1-phosphate-receptor-s1pr-modulator-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Important Acquisition Enhances Vanda Pharmaceuticals' Portfolio
In December 2023, Vanda Pharmaceuticals, based in the United States, secured the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. The financial terms of this deal remain undisclosed. This acquisition is aimed at strengthening Vanda's offerings by adding an innovative treatment for relapsing multiple sclerosis, a condition growing in prevalence and representing a substantial unmet medical need. Actelion, headquartered in Switzerland, focuses on developing S1PR modulator drugs targeting various diseases.
Innovative Trends Poised to Impact the Sphingosine 1 Phosphate Receptor Modulator Drugs Market
Pharmaceutical companies are heavily investing in the development of oral therapies like etrasimod (VELSIPITY) to improve patient compliance, enhance treatment effectiveness, and widen availability for immune-inflammatory disorders. An oral S1PR modulator functions as a small molecule that selectively targets S1P receptors, regulating immune cell movement and diminishing inflammation.
For example, in October 2023, Pfizer received FDA approval for VELSIPITY (etrasimod), designed for moderately to severely active ulcerative colitis. This once-daily oral medication is noted for its high receptor selectivity, favorable safety profile, and ease of dosing, marking a meaningful advancement in oral immunomodulatory treatments.
Detailed Segmentation of the Sphingosine 1 Phosphate Receptor Modulator Drugs Market
This report segments the S1PR modulator drugs market as follows:
1) By Type: Fingolimod, Ozanimod
2) By Route of Administration: Oral, Injectable
3) By Application: Multiple Sclerosis, Cardiovascular Diseases, Transplant Rejection
4) By End User: Hospitals, Rehabilitation Centers, Retail Pharmacies
Further breakdown includes:
- Fingolimod: Branded Formulations, Generic Formulations
- Ozanimod: Oral Capsules, Other Formulations
These classifications provide a comprehensive understanding of key product categories, delivery methods, therapeutic uses, and primary consumers within the market.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top Companies and Market Competition in the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Industry here
News-ID: 4501405 • Views: …
More Releases from The Business Research Company
Percutaneous Puncture Surgery Robot Market Analysis Highlights Growth To $3.54 B …
The market for percutaneous puncture surgery robots is on the verge of significant expansion, driven by rapid technological advances and increasing adoption in healthcare settings. As robotic systems become more sophisticated and integrated with cutting-edge technologies, this sector is set to transform minimally invasive surgical procedures. Below is a detailed exploration of the market's size, key players, trends, and segmentation that shape its future trajectory.
Projected Growth and Market Size of…
Pedicle Screw Systems Market Study Highlights How Industry Demand Is Evolving
The pedicle screw systems market is set to experience significant expansion in the coming years, driven by advancements in spinal surgery techniques and increasing patient demand. This market's evolution reflects growing medical needs and ongoing innovation, positioning it for substantial growth by 2030.
Forecasted Market Size and Growth Trajectory for Pedicle Screw Systems
The value of the pedicle screw systems market is projected to reach $7.65 billion by 2030, growing…
Pediatric Orthopedic Implants Market Research Reveals Strong 10.8% CAGR Outlook …
The pediatric orthopedic implants market is on track for significant expansion as advancements in technology and growing healthcare needs drive demand. Innovations in implant design and personalized treatment options are setting the stage for transformative growth in this specialized segment of medical devices. Below is a detailed overview of the current market size, key industry players, emerging trends, and segmentation that define this market's future.
Pediatric Orthopedic Implants Market Size and…
Pediatric Interventional Cardiology Market Intelligence Report Covers Trends, Se …
The pediatric interventional cardiology field is on track for significant expansion, driven by advances in medical technology and growing demand for specialized cardiac care for children. This sector is expected to see dynamic growth as innovative devices and techniques become more widely adopted to improve patient outcomes.
Projected Market Size and Growth Trajectory of the Pediatric Interventional Cardiology Market
The market for pediatric interventional cardiology is forecasted to grow steadily,…
More Releases for S1P
Secondary Progressive Multiple Sclerosis (SPMS) Drug Market Grows as Oral S1P Mo …
The Secondary Progressive Multiple Sclerosis (SPMS) drug market is entering a more innovation-rich phase. As better diagnostics and longer survival increase the number of patients transitioning from relapsing-remitting MS (RRMS) to SPMS, demand is rising for therapies that slow disability progression, not just reduce relapses. Oral S1P modulators like siponimod, high-efficacy monoclonal antibodies, and late-stage BTK inhibitors are reshaping the treatment landscape and expanding the value of the SPMS segment…
S1P Receptor Modulator Drugs Market Driven by Rising Autoimmune Disease Prevalen …
✅ S1P Receptor Modulator Drugs Market: Unlocking New Frontiers in Autoimmune and Neurological Therapies
The global S1P receptor modulator drugs market is undergoing a transformational shift, driven by rising prevalence of autoimmune and central nervous system disorders such as multiple sclerosis (MS), inflammatory bowel disease, and ulcerative colitis. These drugs, which modulate the sphingosine-1-phosphate (S1P) receptors, help reduce immune cell migration and inflammation, offering an advanced approach in disease management. In…
S1P Receptor Modulator Drugs Market, Unlocking Therapeutic Potential and Market …
Overview of the Market
The global S1P receptor modulator drugs market has emerged as a critical segment in pharmaceutical development, particularly due to its applications in treating autoimmune and inflammatory diseases such as multiple sclerosis (MS) and ulcerative colitis. These drugs work by modulating the sphingosine-1-phosphate (S1P) receptors, which play a vital role in immune cell trafficking, thus helping to reduce the pathological immune responses characteristic of autoimmune diseases. The market…
S1P Receptor Modulator Drugs Market Forecast 2025-2032, Latest Trends and Opport …
S1P Receptor Modulator Drugs Market: A Comprehensive Analysis of Growth Trends and Opportunities
The Sphingosine-1-Phosphate (S1P) receptor modulator drugs market has evolved into a critical segment of the pharmaceutical industry, offering innovative therapeutic approaches to autoimmune diseases such as multiple sclerosis (MS), ulcerative colitis, and Crohn's disease. These modulators target S1P receptors to influence lymphocyte migration, thereby reducing inflammatory responses. With an increasing prevalence of chronic autoimmune conditions and the growing…
S1P Receptor Modulator Drugs Market - Global Trends & Forecasts to 2020-2029
Dhirtek Business Research and Consulting has added a new research report to its vast library. The study report, titled s1p receptor modulator drugs, analyses market trends and dynamics objectively. Analysts compared historical market data to current market patterns to provide a clear picture of the market's direction. The study includes SWOT analysis and Porter's five forces analysis to provide readers with an in-depth overview of the key variables that are…
S1P receptor modulator Drugs Market To Witness a Major Overhaul between 2020 and …
S1P receptor performs basic biological processes such as cell proliferation, migration, cytoskeleton organization, immune cell trafficking and others. S1P receptor modulators are a type of immunomodulatory used in case of multiple sclerosis, psoriasis, inflammatory diseases, and cancer. S1P receptor modulators are used to control the release of lymphocytes in peripheral blood and reach the central nervous system. According to the Multiple Sclerosis Association of America, approximately 3.5 out of 1,000…
